Posts Tagged ‘Eli Lilly and Company’

FDA Approves “An Important Advance,” Tirzepatide

May 14, 2022 — Yesterday, FDA approved tirzepatide for type 2 diabetes, calling it “an important advance.” The brand name will be Mounjaro. This is the same drug for which its maker, Eli Lilly and Company, announced remarkable results in a phase 3 obesity study barely two weeks ago. It is the first of its kind – a dual […]

Tirzepatide Shows Good Weight Outcomes in Diabetes

October 20, 2021 — Day by day, the prospects for treating obesity are getting better. Late on Monday, detailed results from the longest study yet of tirzepatide came out in Lancet. This was a study using this new drug in people with type 2 diabetes, but the average BMI of these patients was 33. None of them had a […]

Tirzepatide and the Search for Better Obesity Treatment

February 22, 2021 — When NEJM recently published impressive results for a new obesity treatment, it caused quite a stir. Now it looks like semaglutide might have some serious competition coming right behind it. Late last week, Lilly announced results for two phase 3 studies of tirzepatide. These were both studies for type-2 diabetes. Effects on body weight were […]

Tirzepatide: Two for One Efficacy? Diabetes + Obesity?

December 10, 2020 — News from Eli Lilly and Company suggests that we may soon see a new drug that offers two-for-one efficacy – a clinical benefit in both obesity and diabetes. The company announced yesterday that tirzepatide produced good results against endpoints for both diseases in a phase 3 RCT. In this study, called SURPASS-1, researchers tested three […]